Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS

American Journal of Ophthalmology

Volumn 133, Issue 4, 2002, Pages 484-498

  Hutcherson, Stephen L ^a   Lanz, René ^b  

^a Cyclix Ltd LLC   (United States)

^b Novartis Ophthalmics AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FOMIVIRSEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTERIOR EYE CHAMBER; ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATION; INTRAOCULAR PRESSURE; PERIPHERAL VISION; PIGMENT DISORDER; PRIORITY JOURNAL; RESEARCH; RETINITIS; VISUAL FIELD;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CLINICAL TRIALS; CYTOMEGALOVIRUS RETINITIS; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INCIDENCE; INJECTIONS; RISK FACTORS; SAFETY; SEVERITY OF ILLNESS INDEX; THIONUCLEOTIDES; VITREOUS BODY;

EID: 0036202847     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(02)01332-6     Document Type: Article

References (47)

1. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed, peripheral cytomegalovirus retinitis in patients with AIDS
2. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS
3. Retinal toxic effects associated with intravitreal fomivirsen
4. Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis
5. The development of antisense oligonucleotides as antivirals
6. Fomivirsen-a phosphorothioate oligonucleotide for the treatment of CMV retinitis
7. Management of cytomegalovirus disease with antiviral drugs
8. Treatment of cytomegalovirus retinitis with ganciclovir
9. A randomized controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
10. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS; the HPMPC peripheral cytomegalovirus retinitis trial. A randomized controlled trial
11. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized controlled trial
12. Complications after implantation of intraocular devices in patients with cytomegalovirus retinitis
13. Outcomes of cytomegalovirus retinitis following the use of ganciclovir implants
14. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant
15. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial
16. High-dose (2000 μg) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis
17. Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis
18. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis
19. Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS
20. Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome
21. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis
22. Immune recovery vitritis associated with inactive cytomegalovirus retinitis; a new syndrome
23. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis
24. Immune recovery uveitis
25. Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis
26. Bilateral cystoid macular edema after successful treatment of AIDS-associated cytomegalovirus retinitis
27. Decreased visual acuity in patients with cytomegalovirus retinitis and AIDS
28. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy
29. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy
30. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy
31. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides
32. Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin
33. Advances in understanding the pharmacological properties of antisense oligonucleotides
34. Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy
35. Inflammatory mediators in the vitreous humor of AIDS patients with retinitis
36. Proinflammatory potential of cytomegalovirus infection. specific inhibition of cytomegalovirus immediate-early expression in combination with antioxidants as a novel treatment strategy?
37. The antisense oligonucleotide ISIS 2922 prevents cytomegalovirus-induced upregulation of IL-8 and ICAM-1 in cultured human fibroblasts
38. The role of CpG motifs in innate immunity
39. Retinal pigment epithelial dysfunction in human immunodeficiency virus-infected patients with cytomegalovirus retinitis
40. Retinal toxicity in human immunodeficiency virus-infected children treated with 2′,3′-dideoxyinosine
41. Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis; the Foscarnet-ganciclovir cytomegalovirus retinitis trial
42. Ocular manifestations of HIV infection
43. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group
44. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis
45. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immunodeficiency syndrome
46. Rhegmatogenous retinal detachments in patients with AIDS and necrotizing retinal infections
47. Local therapy for cytomegalovirus retinopathy